secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001193125-25-065613
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma enters registration rights agreement with Averill funds related to direct offering
--------------------------------------------------------------------------------

- Registration Rights Agreement with Averill Master Fund and Averill Madison Master Fund dated March 26, 2025.
- Company must file resale registration statement for shares sold in direct offering within 60 days of closing.
- Company must use best efforts to have registration declared effective by 90th day (120th if full SEC review).
- Agreement provides customary indemnification obligations between company and purchasers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525065613/0001193125-25-065613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525065613/d933210d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-065613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer